Agenda
Applications for consideration at this meeting
- 1195.1 F-18 flurodeoxyglucose positron emission tomography (FDG PET) for the diagnosis of Alzheimer Disease
- 1446 Hepascore test to diagnose and monitor liver fibrosis severity in chronic liver disease
- 1522 PD-L1 (Programmed Death-Ligand 1) immunohistochemistry testing for access to pembrolizumab as first-line therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma (co-dependent)
- 1532 Expansion of genetic testing for myeloproliferative neoplasms under MBS item 73325
- 1574 Non-Invasive Prenatal Testing (NIPT) for fetal Rhesus D genotype
- 1591 Review of immunoglobulin use for secondary hypogammaglobulinaemia unrelated to haematological malignancies, or post-haemopoietic stem cell transplant
- 1592 Review of immunoglobulin use for primary immunodeficiency diseases with antibody deficiency
- 1595 Closed loop upper airway stimulation for moderate to severe obstructive sleep apnoea, in patients who have failed or are intolerant to, continuous positive airway pressure (CPAP) therapy
- 1597 Cryoablation for biopsy-confirmed renal cell carcinoma (RCC) ≤4cm in patients not suitable for partial nephrectomy
- 1598 Genetic testing for diagnosis of inheritable cardiac rhythm disorders
- 1602 Testing for neurotrophic tyrosine receptor kinase (NTRK) gene fusion status, in patients with locally advanced or metastatic solid tumours, to determine eligibility for larotrectinib
- 1603 Transcatheter aortic valve implantation (TAVI) via transfemoral delivery, using the SAPIEN 3 balloon-expandable valve (BEV) system, for patients at intermediate risk for surgery
- 1605 Transcatheter delivery of a dual-filter cerebral embolic protection system during transcatheter aortic valve implantation
- 1623 Voretigene neparvovec (Luxturna) for the treatment of biallelic RPE-65-mediated Inherited Retinal Dystrophies
- 1638 Proton beam therapy for paediatric and rare cancers
- 1653 Amendment to eligibility criteria for tisagenlecleucel for treatment of relapsed or refractory diffuse large B-cell lymphoma - removal of the requirement for patients to be “CD19-positive”
Related information
Committee: